Companies
Gilead Sciences
PharmaceuticalsFoster City, CaliforniaGILDAbout 17,000 employees
More about Gilead Sciences
Biotech company that develops and sells medicines for HIV, liver disease, cancer and inflammatory conditions
Revenue
$29.4B
Fiscal 2025, up 2.4%
Employees
About 17,000
As of December 2025
Stock
GILD
Nasdaq
Headquarters
Foster City, California
CEO
Daniel O'Day
Since March 2019
BrandsBiktarvy, Descovy, Yeztugo, Veklury, Trodelvy, Kite
Current strategyMaximizing long-acting HIV treatments, building its oncology and inflammation pipeline, and adopting AI across the business
Recent workforce changes192 roles cut in Rockville, Maryland and Redwood City, California in June 2026
CompetitorsViiV Healthcare, Merck, AbbVie
Checked October 11, 2026 · Sources: sec.gov, warntracker.com
No source-backed updates for Gilead Sciences yet. They appear here when a public report or filing covers the company.
No one has posted about Gilead Sciences yet. Be the first to post ›
Follow Gilead Sciences in a feed reader, no account needed: RSS feed